Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Osimertinib 80 mg in EGFR-Mutant NSCLC With Leptomeningeal Metastases
KCT0005540Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), Carcinomatous Meningitis (CM), sponsored by AstraZeneca. Started Dec 2020; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)Carcinomatous Meningitis (CM)
Beyond the preview
Go deeper on KCT0005540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005540.